HBK Investments’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-9,400
Closed -$345K – 403
2023
Q2
$345K Sell
9,400
-74,500
-89% -$2.9M ﹤0.01% 347
2023
Q1
$3.42M Buy
+83,900
New +$3.62M 0.02% 118
2022
Q4
– Sell
-70,200
Closed -$3.07M – 165
2022
Q3
$3.07M Sell
70,200
-163,000
-70% -$7.92M 0.02% 259
2022
Q2
$12.2M Buy
233,200
+174,800
+299% +$8.91M 0.07% 86
2022
Q1
$3.02M Buy
+58,400
New +$3.03M 0.01% 360
2021
Q3
– Sell
-232,700
Closed -$9.11M – 858
2021
Q2
$9.11M Buy
232,700
+159,400
+217% +$6.2M 0.03% 135
2021
Q1
$2.66M Buy
+73,300
New +$2.6M 0.01% 423
2020
Q1
– Sell
-93,806
Closed -$3.49M – 395
2019
Q4
$3.49M Sell
93,806
-9,064
-9% -$323K 0.03% 347
2019
Q3
$3.51M Sell
102,870
-11,805
-10% -$429K 0.04% 331
2019
Q2
$4.71M Sell
114,675
-151,882
-57% -$6.03M 0.04% 245
2019
Q1
$10.7M Buy
+266,557
New +$10.7M 0.11% 153

Other funds holding PFE

HBK Investments's PFE Position: Q2 2026 in Review

HBK Investments sold out of Pfizer (PFE) in Q2 2026, closing a stake of 10,878 shares — an estimated $305K sold.

HBK Investments first reported a position in PFE in Q4 2015 and held it in 8 quarters. The position peaked at $33.6M in Q1 2019. 2,842 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • HBK Investments reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • HBK Investments sold 10,878 Pfizer shares in Q2 2026, an estimated $305K.
  • HBK Investments first reported a position in Pfizer in Q4 2015 and held it in 8 quarters.
  • HBK Investments's Pfizer position peaked at $33.6M in Q1 2019.
  • 2,842 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on HBK Investments's 13F filing for Q2 2026, filed 14 Aug 2026.